Vaxvec

Human adenoviral vectors
Vaxvec ID	35
Vaccine Vector Name	Human adenoviral vectors
Alternative Names	HAd
Vector VO ID	VO_0001087
Advantage	HAd5 is the best characterized of all adenoviruses (Bangari and Mittal, 2006).
Disadvantage	The employment of adenoviral vectors in clinical vaccine applications is thought to be limited by pre-existing immunity to the vector or immunity that rapidly develops after the first inoculation with adenoviral vectors (Bangari and Mittal, 2006).
Safety	Ad vectors appear to be safe for use in humans as human Ad (HAd) serotype 4 and 7 have been used as live oral vaccines in military recruits in the USA for several decades without any known adverse effects (Bangari and Mittal, 2006).
Related Vaccine(s)	Recombinant vector vaccine AdC68- rabies virus glycoprotein (Rabies virus) rAd-GP (Ebola virus) (Ebola virus)
References	Bangari and Mittal, 2006: Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine. 2006; 24(7); 849-862. [PubMed: 16297508]. Barouch and Nabel, 2005: Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Human gene therapy. 2005; 16(2); 149-156. [PubMed: 15761255].